Intramuscular immunization with p36(LACK) DNA vaccine induces IFN-γ production but does not protect BALB/c mice against Leishmania chagasi intravenous challenge

Parasitology Research

Volumn 98, Issue 1, 2005, Pages 67-74

  Marques Da Silva, Eduardo A ^a   Coelho, Eduardo A F ^b,c   Gomes, Daniel C O ^a   Vilela, Márcia C ^a   Masioli, Cássio Z ^a   Tavares, Carlos A P ^b   Fernandes, Ana Paula ^c   Afonso, Luis Carlos C ^a   Rezende, Simone A ^a  

^a FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

^b ICB   (Brazil)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

IFN ; IL 10; IL 4; Lack; Leishmania chagasi; Vaccine

Indexed keywords

CYTOKINE; DNA VACCINE; GAMMA INTERFERON; INTERLEUKIN 10; LEISHMANIA HOMOLOGUE OF RECEPTORS FOR ACTIVATED C KINASE DNA VACCINE; PARASITE ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; IMMUNIZATION; LEISHMANIA CHAGASI; LIVER; MOUSE; NONHUMAN; PARASITE; PRIORITY JOURNAL; PROTECTION; PROTOZOAL INFECTION; SPLEEN; SPLEEN CELL; VACCINATION;

ANIMALS; ANTIGENS, PROTOZOAN; DISEASE MODELS, ANIMAL; FEMALE; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-4; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; LIVER; LYMPHOCYTES; MICE; MICE, INBRED BALB C; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; SPLEEN; VACCINES, DNA;

ANIMALIA; LEISHMANIA DONOVANI CHAGASI; LEISHMANIA MAJOR;

EID: 27944452329     PISSN: 09320113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00436-005-0008-8     Document Type: Article

References (22)

1. Afonso LC, Scott P (1993) I. Immune responses associated with susceptibility of C57BL/10 mice to Leishmania amazonensis. Infect Immun 61:2952-2959
2. Ahmed S, Colmenares M, Soong L, Goldsmith-Pestana K, Munstermann L, Molina R, McMahon-Pratt D (2003) Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasis. Infect Immun 71:401-410
3. Belkaid YS, Kamhawi G, Modi G, Valenzuela N, Noben-Trauth E, Rowton J, Sacks DL (1998) Development of a natural model of cutaneous leishmaniasis: powerful effects of vector saliva and saliva preexposure on the long-term outcome of Leishmania major infection in the mouse ear dermis. J Exp Med 188:1941-1946
4. Bogdan C, Vodovotz Y, Nathan CF (1991) Macrophage deactivation by interleukin-10. J Exp Med 174:1549-1555
5. + T-cell responses against malaria liver stages. Nat Med 8(2):166-170
6. Coelho EAF, Tavares CAP, Carvalho FAA, Chaves KF, Teixeira KN, Rodrigues RC, Charest H, Matlashewski G, Gazzinelli RT, Fernandes AP (2003) Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection. Infect Immun 71:3988-3994
7. Ghosh A, Zhang WW, Matlashewski G (2002) Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. Vaccine 12 20(1-2):59-66
8. Gurunathan S, Sacks DL, Brown DR, Reiner SL, Charest H, Glaichenhaus N, Seder RA (1997) Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med 186(7):1137-1147
9. + T cells. J Immunol 165:915-924
10. Heinzel FP, Sadick MD, Holaday BJ, Coffman RL, Locksley RM (1989) Reciprocal expression of IFN-γ or IL-4 during the resolution or progression of murine leishmaniasis. Evidence of expansion of distinct helper T cell subsets. J Exp Med 169:59-72
11. Humphreys NE, Grencis RK (2002) Effects of ageing on the immunoregulation of parasitic infection. Infect Immun 70(9):5148-5157
12. Kaye PM, Curry AJ, Blackwell JM (1991) Differential production of Th1 and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. J Immunol 146:2763-2770
13. Lowry OH, Rosebrough NF, Farr AL, Randal RJ (1995) Protein measurement with Folin-phenol reagent. J Biol Chem 193-265
14. Melby PC, Yang J, Zhao W, Perez LE, Cheng J (2001) Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect Immun 69:4719-4725
15. Mougneau E, Altare F, Wakil AE, Zheng S, Coppola T, Wang AZE, Waldmann R, Locksley RM, Glaichenhaus N (1995) Expression cloning of a protective Leishmania antigen. Science 268:563-566
16. Pearson RD, Sousa AQ (1996) Clinical spectrum of leishmaniasis. Clin Infect Dis 22:1-13
17. Ramiro MJ, Zarate JJ, Hanke T, Rodrigues D, Rodriguez JR, Esteban M, Lucientes J, Castillo JA, Larraga V (2003) Protection in dogs against visceral leishmaniasis caused by L. infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK. Vaccine 21:2474-2484
18. Stager S, Alexander J, Carter KC, Brombacher F, Kaye PM (2003) Both interleukin-4 (IL-4) and IL-4 receptor alpha signaling contribute to the development of hepatic granulomas with optimal antileishmanial activity. Infect Immun 71(8):4804-4807
19. Titus RG, Marchand M, Boon T, Louis JA (1985) A limiting dilution assay for quantifying Leishmania infectivity. Parasite Immunol 7:545-555
20. Uzonna JE, Spath GF, Beverley SM, Scott P (2004) Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response. J Immunol 172:3793-3797
21. Vilela MC, Afonso LCC, Rezende SA (2002) Heterologous protection by Leishvacin® in Leishmania chagasi infection of BALB/c mice. Rev Inst Med Trop Sao Paulo 44:133
22. Wilson ME (1993) Leishmaniasis. Curr Opin Infect Dis 6:331-340